Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.98 |
| ▸ | ITGB6 | P18564 | 12/20 | 0.98 |
| ▸ | ITGB8 | P26012 | 12/20 | 0.98 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.74 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17999155 | 0.99 | ITGAV (1.00) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL29707571 | 0.99 | ITGAV (1.00) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL18029432 | 0.99 | ITGAV (1.00) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL18029471 | 0.91 | ITGAV (0.82) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL18029439 | 0.91 | ITGAV (0.82) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL18029429 | 0.90 | ITGAV (0.83) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL18029430 | 0.90 | ITGAV (0.83) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL23790346 | 0.85 | ITGAV (0.98) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL18029427 | 0.84 | ITGAV (1.00) | ITGAVITGB6ITGB8ITGB3ITGB5 | |
| SCHEMBL17999138 | 0.84 | ITGAV (1.00) | ITGAVITGB6ITGB8ITGB3ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685738-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | OCUTERRA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210277000-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FELIQS CORPORATION (JP) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685738-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | FFAR3, FFAR2, FFAR1 | ITGAV 1161/4885ITGB6 1373/4885ITGB8 2346/4885 |
| US-20210277000-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | ITGAV 1161/4885ITGB6 1373/4885ITGB8 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.